KBC Group NV Lowers Stock Holdings in Repligen Co. (NASDAQ:RGEN)

KBC Group NV cut its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 64.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,969 shares of the biotechnology company’s stock after selling 5,483 shares during the quarter. KBC Group NV’s holdings in Repligen were worth $442,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in RGEN. Vanguard Group Inc. grew its position in Repligen by 0.4% during the first quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock valued at $937,994,000 after acquiring an additional 21,719 shares during the period. Bank of New York Mellon Corp raised its holdings in Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after buying an additional 237,884 shares during the period. Conestoga Capital Advisors LLC lifted its position in Repligen by 26.7% during the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after buying an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Repligen by 240.5% in the second quarter. Thrivent Financial for Lutherans now owns 601,829 shares of the biotechnology company’s stock worth $75,866,000 after acquiring an additional 425,061 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Repligen by 14.4% in the 3rd quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company’s stock valued at $84,387,000 after acquiring an additional 71,274 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on RGEN shares. UBS Group decreased their price target on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research report on Wednesday, November 13th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Activity at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Repligen Stock Performance

Repligen stock opened at $128.49 on Wednesday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average of $140.67 and a 200-day moving average of $143.94. The stock has a market cap of $7.20 billion, a P/E ratio of -347.26, a price-to-earnings-growth ratio of 3.75 and a beta of 0.96. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $211.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter last year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. On average, analysts expect that Repligen Co. will post 1.52 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.